Yorvipath (palopegteriparatide)
OrphanAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- palopegteriparatide
- Company
- Ascendis Pharma Bone Diseases A/S
- Status
- Authorised
- Therapeutic area
- Hypoparathyroidism
- CHMP opinion
- Thu 14 Sep 2023
- EU approval
- Fri 17 Nov 2023
- Designations
- Orphan, Additional monitoring
- Application
- EMEA/H/C/005934
- ATC
- H05AA
- Official record
- www.ema.europa.eu
Indication
Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
Regulatory milestones
No milestones recorded in the last year.
Follow Yorvipath
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.